Sage Therapeutic Com (SAGE)

Feb 14, 2025, 10:00 AM EST - 8 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out

Feb 13, 2025, 10:00 AM EST - 9 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation

Feb 12, 2025, 10:00 AM EST - 10 days ago

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Feb 11, 2025, 9:29 PM EST - 11 days ago

Sage Therapeutics, Inc. (SAGE) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 4:05 PM EST - 11 days ago

Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates

Feb 11, 2025, 10:00 AM EST - 11 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation

Feb 10, 2025, 10:00 AM EST - 12 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Connect

Feb 9, 2025, 10:00 AM EST - 13 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities Investigation

Feb 7, 2025, 10:00 AM EST - 15 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation

Feb 6, 2025, 10:00 AM EST - 16 days ago

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 4, 2025, 10:00 AM EST - 18 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect

Feb 3, 2025, 10:00 AM EST - 19 days ago

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Feb 2, 2025, 10:00 AM EST - 20 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation

Jan 31, 2025, 10:00 AM EST - 22 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation

Jan 30, 2025, 10:30 AM EST - 23 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Reach Out

Jan 28, 2025, 4:30 PM EST - 25 days ago

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Jan 27, 2025, 9:20 AM EST - 26 days ago

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen's Unsolicited Acquisition Proposal

Jan 24, 2025, 1:38 PM EST - 4 weeks ago

Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm

Jan 13, 2025, 10:40 AM EST - 5 weeks ago

Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid

BIIB

Jan 13, 2025, 9:38 AM EST - 5 weeks ago

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?

Jan 13, 2025, 7:24 AM EST - 5 weeks ago

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen

BIIB

Jan 12, 2025, 6:00 PM EST - 5 weeks ago

Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference

Jan 10, 2025, 6:49 PM EST - 6 weeks ago

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

BIIB

Jan 8, 2025, 6:30 AM EST - 6 weeks ago

Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

Nov 26, 2024, 7:00 AM EST - 3 months ago

Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 10:36 AM EST - 3 months ago

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder

Nov 20, 2024, 7:34 AM EST - 3 months ago

Sage Therapeutics to end Huntington's disease trial after key therapy fails again

Nov 20, 2024, 6:58 AM EST - 3 months ago

Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study

Nov 20, 2024, 6:30 AM EST - 3 months ago

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease

Oct 29, 2024, 9:35 PM EDT - 4 months ago

Sage Therapeutics, Inc. (SAGE) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 4:05 PM EDT - 4 months ago

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates

Oct 27, 2024, 11:00 AM EDT - 4 months ago

DEADLINE TOMORROW: Sage Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm

Oct 25, 2024, 11:00 AM EDT - 4 months ago

Sage Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Reach Out To The Schall Law Firm

Oct 23, 2024, 12:58 PM EDT - 4 months ago

Rosen Law Firm Urges Sage Therapeutics, Inc. (NASDAQ: SAGE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Oct 23, 2024, 11:00 AM EDT - 4 months ago

Sage Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm

Oct 22, 2024, 5:52 PM EDT - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics